[Early measurement of digoxin concentration in blood serum to predict adverse events in older age groups with chronic heart failure and atrial fibrillation.]
{"title":"[Early measurement of digoxin concentration in blood serum to predict adverse events in older age groups with chronic heart failure and atrial fibrillation.]","authors":"A A Yakovlev, G A Ryzhak, A S Pushkin","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>To evaluate the effect of early measurement of serum digoxin concentration (SDC) on therapeutical safety and efficacy in patients with recent-onset atrial fibrillation and heart failure. De novo ventricular arrhythmias, high-grade AV node or sinus node blocks were noted in 22%, this risk was positively associated with endpoint SDC (mean SDC 0,88±0,78 ng/mL vs 0,45±0,71 ng/mL, p=0,039) irrespective of baseline characteristics. Empiric calculators for long-term digoxin monitoring correlated with both SDC (r=0,54...0,58, p=0,008...0,003) and risk of conductivity disturbances. Re-hospitalizations by urgent cardiovascular indications within 10 months were associated with higher endpoint SDC (0,82±0,77 ng/mL in hospitalized patients vs 0,42±0,44 ng/mL in non-hospitalized, p=0,009), with no association between early SDC and deaths. Early SDC monitoring may minimize the risk of adverse events in the treatment of atrial fibrillation. Existing empirical SDC calculators can also be used in clinical practice, but their predictive value for assessing the long-term safety of digoxin therapy remains unclear and requires further study.</p>","PeriodicalId":35293,"journal":{"name":"Advances in gerontology = Uspekhi gerontologii / Rossiiskaia akademiia nauk, Gerontologicheskoe obshchestvo","volume":"37 4","pages":"344-351"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in gerontology = Uspekhi gerontologii / Rossiiskaia akademiia nauk, Gerontologicheskoe obshchestvo","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
To evaluate the effect of early measurement of serum digoxin concentration (SDC) on therapeutical safety and efficacy in patients with recent-onset atrial fibrillation and heart failure. De novo ventricular arrhythmias, high-grade AV node or sinus node blocks were noted in 22%, this risk was positively associated with endpoint SDC (mean SDC 0,88±0,78 ng/mL vs 0,45±0,71 ng/mL, p=0,039) irrespective of baseline characteristics. Empiric calculators for long-term digoxin monitoring correlated with both SDC (r=0,54...0,58, p=0,008...0,003) and risk of conductivity disturbances. Re-hospitalizations by urgent cardiovascular indications within 10 months were associated with higher endpoint SDC (0,82±0,77 ng/mL in hospitalized patients vs 0,42±0,44 ng/mL in non-hospitalized, p=0,009), with no association between early SDC and deaths. Early SDC monitoring may minimize the risk of adverse events in the treatment of atrial fibrillation. Existing empirical SDC calculators can also be used in clinical practice, but their predictive value for assessing the long-term safety of digoxin therapy remains unclear and requires further study.